{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Opioid+Placebo&page=2", "query": { "intervention": "Opioid Placebo", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Opioid+Placebo&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-28T12:50:36.672Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04325802", "title": "Treatment of Chronic Itch in Atopic Dermatitis With Opioid Antagonist Naltrexone", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis", "Pruritus", "Pruritus Chronic", "Dermatitis" ], "interventions": [ { "name": "Naltrexone", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 0, "start_date": "2022-12-31", "completion_date": "2024-06", "has_results": false, "last_update_posted_date": "2023-04-04", "last_synced_at": "2026-09-28T12:50:36.672Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04325802" }, { "nct_id": "NCT02696434", "title": "Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Opioid Use Disorder" ], "interventions": [ { "name": "Naltrexone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Buprenorphine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alkermes, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 101, "start_date": "2016-04", "completion_date": "2017-11-30", "has_results": true, "last_update_posted_date": "2019-02-12", "last_synced_at": "2026-09-28T12:50:36.672Z", "location_count": 9, "location_summary": "Lauderhill, Florida • Oakland Park, Florida • Winfield, Illinois + 6 more", "locations": [ { "city": "Lauderhill", "state": "Florida" }, { "city": "Oakland Park", "state": "Florida" }, { "city": "Winfield", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Berlin", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02696434" }, { "nct_id": "NCT06406400", "title": "Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2).", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Opioid Use Disorder" ], "interventions": [ { "name": "AZD4041", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" }, { "name": "Buprenorphine", "type": "DRUG" }, { "name": "Buprenorphine / Naloxone", "type": "DRUG" }, { "name": "Hydromorphone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 15, "start_date": "2024-05-13", "completion_date": "2024-07-31", "has_results": false, "last_update_posted_date": "2025-03-26", "last_synced_at": "2026-09-28T12:50:36.672Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06406400" }, { "nct_id": "NCT06111339", "title": "Ketamine for OUD and Suicidal Ideation in the ED", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Opioid Use Disorder", "Suicidal Ideation" ], "interventions": [ { "name": "Ketamine", "type": "DRUG" }, { "name": "Saline Solution", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2024-06-14", "completion_date": "2025-03-31", "has_results": false, "last_update_posted_date": "2025-04-08", "last_synced_at": "2026-09-28T12:50:36.672Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06111339" }, { "nct_id": "NCT03237481", "title": "Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Postoperative Pain" ], "interventions": [ { "name": "HTX-011", "type": "DRUG" }, { "name": "Bupivacaine HCl", "type": "DRUG" }, { "name": "Saline placebo", "type": "DRUG" }, { "name": "Luer-lock applicator", "type": "DEVICE" }, { "name": "Vial access device", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Heron Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 418, "start_date": "2017-07-31", "completion_date": "2018-01-16", "has_results": true, "last_update_posted_date": "2026-03-02", "last_synced_at": "2026-09-28T12:50:36.672Z", "location_count": 22, "location_summary": "Florence, Alabama • Sheffield, Alabama • Phoenix, Arizona + 18 more", "locations": [ { "city": "Florence", "state": "Alabama" }, { "city": "Sheffield", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Bakersfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03237481" }, { "nct_id": "NCT07204171", "title": "Phase 1 Study of Oral MG001", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Safety and Tolerability in Healthy Subjects" ], "interventions": [ { "name": "mitragynine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute on Drug Abuse (NIDA)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 32, "start_date": "2026-09", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-06-16", "last_synced_at": "2026-09-28T12:50:36.672Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07204171" }, { "nct_id": "NCT05669027", "title": "Mobile Neurofeedback for Low Back Pain", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Chronic Low Back Pain" ], "interventions": [ { "name": "Neurofeedback", "type": "DEVICE" }, { "name": "Sham (Placebo Control)", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 150, "start_date": "2023-10-02", "completion_date": "2027-05-01", "has_results": false, "last_update_posted_date": "2025-12-17", "last_synced_at": "2026-09-28T12:50:36.672Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05669027" }, { "nct_id": "NCT01887990", "title": "Treatment of Suicidal Ideation With Intravenous Ketamine Infusion", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Depression", "Suicidal Ideation" ], "interventions": [ { "name": "Ketamine", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 18, "start_date": "2012-05", "completion_date": "2014-01", "has_results": true, "last_update_posted_date": "2017-05-15", "last_synced_at": "2026-09-28T12:50:36.672Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT01887990" }, { "nct_id": "NCT00693160", "title": "Effect of Spinal Ketorolac After Acute Opioid Exposure", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "ketorolac", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "remifentanil", "type": "DRUG" }, { "name": "Capsaicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 30, "start_date": "2007-12", "completion_date": "2011-01", "has_results": true, "last_update_posted_date": "2018-09-07", "last_synced_at": "2026-09-28T12:50:36.672Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00693160" }, { "nct_id": "NCT06992427", "title": "High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8" ], "interventions": [ { "name": "Gabapentin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Chemotheraphy", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Analgesic Agent", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 228, "start_date": "2025-06-05", "completion_date": "2031-04-15", "has_results": false, "last_update_posted_date": "2026-05-11", "last_synced_at": "2026-09-28T12:50:36.672Z", "location_count": 200, "location_summary": "Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 162 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06992427" } ] }